Kyntra Bio Inc Dossier
Qualitative Analysis
Business overview
Kyntra Bio Inc. (formerly FibroGen, Inc.) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics in oncology and rare diseases. Following a series of late-stage clinical trial failures and a strategic restructuring, the company rebranded from FibroGen to Kyntra Bio in January 2026, shifting its primary focus toward oncology and rare disease assets. The company's lead clinical candidate is FG-3246 (also known as FOR46), a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, which is currently in Phase 2 development for metastatic castration-resistant prostate cancer (mCRPC). Kyntra Bio is also developing FG-3180, a companion PET imaging agent designed to evaluate CD46 expression and guide patient selection. Additionally, the company continues to advance roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, which is approved in Europe, Japan, and other international territories for chronic kidney disease (CKD) anemia through its partner Astellas Pharma, and is being prepared for Phase 3 development in lower-risk myelodysplastic syndromes (LR-MDS).
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Rebranding from FibroGen, Inc. to Kyntra Bio, Inc. to reflect a sharpened corporate strategy focused on mid- and late-stage assets in oncology and rare diseases.
Expected impact: Aims to maximize shareholder value and patient impact by prioritizing high-potential assets like FG-3246 and roxadustat.
Advancing FG-3246, a first-in-class CD46-targeting antibody-drug conjugate (ADC), through a Phase 2 monotherapy dose-optimization trial in patients with metastatic castration-resistant prostate cancer (mCRPC).
Expected impact: To establish a competitive progression-free survival profile and validate CD46 as a viable therapeutic target in prostate cancer.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
AstraZeneca collaborates on the development and commercialization of roxadustat. In August 2025, Kyntra Bio sold its China roxadustat operations (FibroGen China) to AstraZeneca for $220.4 million, while retaining rights in the U.S., Canada, Mexico, and other non-partnered markets.
Terms: The divestiture of FibroGen China was completed for approximately $220.4 million in total consideration.
Astellas is collaborating on the commercialization of roxadustat (EVRENZO) for the treatment of anemia in territories including Japan, Europe, Turkey, Russia, the Commonwealth of Independent States, the Middle East, and South Africa.
Terms: Revenue is driven by collaboration agreements, licensing, and potential milestone payments.
Kyntra Bio in-licensed FG-3246 from Fortis Therapeutics, securing an exclusive option to acquire Fortis Therapeutics to fully consolidate the asset.
Terms: Acquired at no upfront cost, with a large milestone payment due only if the drug advances into Phase 3 clinical trials.